Market Pulse: Cytokinetics won't proceed with portion of Ispinesib trial
28th Sep 2005, 12:01 GMT
Biotech company Cytokinetics said after 's closing bell that its Ispinesib drug candidate didn't demonstrate sufficient anti-tumor activity to proceed in the platinum-refractory arm of its Phase II non-small cell lung cancer clinical trial.